NasdaqCM:CGENBiotechs
Compugen (CGEN) Stock Holds Steady As Cash Runway Extends To 2029
Compugen stock barely flinched after earnings, ticking up about 1% to US$2.38, yet the real story sits far beyond today’s modest move. You are looking at a biotech that has just posted another small quarter of revenue at US$2.6m and a quarterly net loss of about US$7m, while still carrying a price tag of only 6.4x trailing earnings.
The time horizon is the tension. In the short term, Q2 is about controlled burn and a long cash runway into 2029. Over multiple years, the debate shifts to...